Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To evaluate the effectiveness of flexible doses (15-30mg) of Aripiprazole in the treatment of patients with schizophrenia and co-morbid symptoms of OCD in the outpatient setting. The overall effectiveness of Aripiprazole will be evaluated by use of the Brief Psychiatric Rating Scale(BPRS), Yale-Brown OCD scale and Clinical Global Impression-Improvement(CGI-I) scale.
| Condition | Intervention |
|---|---|
|
Schizophrenia OCD Obsessive Compulsive Disorder |
Drug: Aripiprazole |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | "Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)". |
- The overall effectiveness of Aripiprazole will be evaluated by use of the BPRS, Yale-Brown OCD scale and Clinical Global Impression-Improvement (CGI-I) scale, including efficacy in reduction of psychosis and obsessions.Improvements in YBOCS and BPRS scor [ Time Frame: weekly ] [ Designated as safety issue: No ]
- Physical Examination, Psychiatric evaluation with YBOCS, BPRS and CGI scales, EPS scale, routine hematology and chemistry tests, urinalysis,urine drug screening,urine pregnancy test, ECG recording [ Time Frame: weekly ] [ Designated as safety issue: Yes ]
| Enrollment: | 10 |
| Study Start Date: | March 2005 |
| Study Completion Date: | May 2008 |
| Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
-
Drug: Aripiprazole
Symptoms of OCD is a rather common co-morbid condition in patients with Schizophrenia. Some studies suggest that obsessive-compulsive symptoms may be present in 7.8-46% of schizophrenic patients and who seem to be poorly responsive to drug therapy. The serotonergic medications in combination with cognitive-behavioral therapy stil remain the preferred treatment for OCD symptoms. There are controversial data regarding effect of neuroleptics on symptoms of OCD. It was noted that the use of Risperdone, Quatiapine and Clozapine might aggravate OCD symptoms. Serotonin antagonism of these neuroleptics is believed to exacerbate obsessive-compulsive symptoms in schizophrenia. On the other hand, Pourovsky M. at(2000) reported three cases of Schizophrenia with symptoms of OCD successfully treated with Olanzapine.One of our patients with Schizophrenia and co-morbid symptoms of OCD who was unsuccessfully treated with various neuroleptics in combination with anti-obsessive agents,demonstrated significant improvement in both Schizophrenic and obsessive compulsive symptoms after she was switched to Aripiprazole. This result encouraged us to initiate pilot study of effectiveness of Aripiprazole in the treatment of specific population of schizophrenic patients with symptoms of OCD.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Man and Women 18-65 years of age.
- Patients who are capable of giving Informed Consent and fluent in English.
- Patients who have DSM IV -Diagnosis of schizophrenia with co-morbid OCD symptoms and BPRS score averaging from mild to moderate (3-4).
- Patients whose obsessive symptoms are not optimally controlled and require a change of treatment.YBOCS score of more than 16.
Exclusion Criteria:
- Outside the age range of 18-65 years.
- Patients with current evidence(past three months) of substance abuse.
- Women of child bearing age who are unwilling to use acceptable methods of contraception.
- Patients who have had recent treatment with long-acting antipsychotic.
- Patients who are suicidal or who have history of recent suicidal attempt.
- History of significant medical condition e.g. seizures, cardiovascular, endocrine,gastrointestinal,renal or respiratory diseases.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00374348
| United States, New York | |
| Jamaica Hospital Medical Center Department of Psychiatry | |
| Jamaica, New York, United States, 11418 | |
| Principal Investigator: | Isak Isakov, M.D. | Jamaica Hospital Medical Center |
More Information
No publications provided
| Responsible Party: | Isak Isakov, MD, Department of Psychiatry Research Division |
| ClinicalTrials.gov Identifier: | NCT00374348 History of Changes |
| Other Study ID Numbers: | JH-PSY-Aripiprazole/Schiz/OCD |
| Study First Received: | September 7, 2006 |
| Last Updated: | September 15, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Jamaica Hospital Medical Center:
|
Schizophrenia with OCD Schizophrenia with-comorbid symptoms of Obsessive Compulsive Disorder(OCD) |
Additional relevant MeSH terms:
|
Compulsive Personality Disorder Obsessive-Compulsive Disorder Schizophrenia Anxiety Disorders Mental Disorders Personality Disorders Schizophrenia and Disorders with Psychotic Features Aripiprazole |
Antipsychotic Agents Central Nervous System Agents Central Nervous System Depressants Pharmacologic Actions Physiological Effects of Drugs Psychotropic Drugs Therapeutic Uses Tranquilizing Agents |
ClinicalTrials.gov processed this record on March 03, 2015